New chemo combo shows promise against tough breast cancer
NCT ID NCT01525966
First seen Apr 03, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study tested a two-drug chemotherapy given before surgery for people with a fast-growing type of breast cancer called triple negative. The goal was to see if the treatment could shrink tumors enough that no cancer remained at the time of surgery. About 67 adults with advanced or inflammatory breast cancer took part. The approach aims to improve outcomes by reducing the amount of tissue that needs to be removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope- South Pasadena Cancer Center
South Pasadena, California, 91030, United States
Conditions
Explore the condition pages connected to this study.